Do children infected with HIV receiving HAART need to be revaccinated?

The Lancet Infectious Diseases

Volumn 10, Issue 9, 2010, Pages 630-642

  Sutcliffe, Catherine G ^a   Moss, William J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; VARICELLA ZOSTER VACCINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BCG VACCINE; HAEMOPHILUS VACCINE;

CD4+ T LYMPHOCYTE; CHICKENPOX; CLINICAL TRIAL; COUGHING; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FINGER PAIN; HEALTH CARE POLICY; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INFLUENZA VIRUS A H1N1; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALAISE; MEASLES; MUMPS; NAUSEA; NEUTROPENIA; OTITIS MEDIA; PAIN; PATIENT MONITORING; PHARYNGITIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RASH; REVACCINATION; REVIEW; RUBELLA; SINUSITIS; TETANUS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VOMITING; WHEEZING; CHILD; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IMMUNOLOGY; INFANT; PHYSIOLOGY; PRESCHOOL CHILD; VACCINATION; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BCG VACCINE; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HIV; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; INFANT; VACCINATION; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION;

EID: 77955854978     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70116-X     Document Type: Review

References (64)

1. Immunization Policy: WHO document WHO/EPI/GEN/95.03, 25-57 1996, Global Programme for Vaccines and Immunization, World Health Organization, Geneva.
2. Global Advisory Committee on Vaccine Safety, 29-30 November 2006. Wkly Epidemiol Rec 2007, 82:18-24. WHO.
3. Measles vaccines: WHO position paper. Wkly Epidemiol Rec 2009, 84:349-360. WHO.
4. Moss W, Halsey N Vaccination of human immunodeficiency virus-infected persons. Vaccine 2008, Saunders, Philadelphia, PA. 5th edn. S. Plotkin, W. Orenstein, P. Offit (Eds.).
5. Moss WJ, Scott S, Mugala N, et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis 2007, 196:347-355.
6. Sanchez JM, Amador JT Ramos, de Miguel S Fernandez, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003, 22:863-867.
7. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection: Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000, 284:190-197.
8. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003, 327:1019.
9. Resino S, Resino R, Bellon J Maria, et al. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis 2006, 43:243-252.
10. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006, 296:292-300.
11. Gibb DM, Newberry A, Klein N, et al. Immune repopulation after HAART in previously untreated HIV-1-infected children: Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Lancet 2000, 355:1331-1332.
12. Vigano A, Vella S, Saresella M, et al. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS 2000, 14:251-261.
13. Borkowsky W, Stanley K, Douglas SD, et al. Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children. J Infect Dis 2000, 182:96-103.
14. 2008 Report on the global AIDS epidemic 2008, UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva.
15. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report June 2008 2009, WHO, World Health Organization, Geneva.
16. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008, 8:477-489.
17. Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa. J Acquir Immune Defic Syndr 2008, 49:523-531. KIDS-ART-LINC Collaboration.
18. Scott S, Mossong J, Moss WJ, et al. Predicted impact of the HIV-1 epidemic on measles in developing countries: results from a dynamic age-structured model. Int J Epidemiol 2008, 37:356-367.
19. Blazevic V, Jankelevich S, Steinberg SM, et al. Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responses. Clin Diagn Lab Immunol 2001, 8:943-948.
20. Hainaut M, Ducarme M, Schandene L, et al. Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2003, 22:62-69.
21. Peruzzi M, Azzari C, Galli L, et al. Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virological failure. Clin Exp Immunol 2002, 128:365-371.
22. Ghosh S, Feyen O, Jebran AF, et al. Memory B cell function in HIV-infected children-decreased memory B cells despite ART. Pediatr Res 2009, 66:185-190.
23. Essajee SM, Kim M, Gonzalez C, et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS 1999, 13:2523-2532.
24. Rosenblatt HM, Song LY, Nachman SA, et al. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol 2005, 116:698-703.
25. Abzug MJ, Song LY, Fenton T, et al. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics 2007, 120:e1190-e1202.
26. Ching N, Deville JG, Nielsen KA, et al. Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART). Eur J Pediatr 2007, 166:51-56.
27. Luzuriaga K, McManus M, Catalina M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000, 74:6984-6991.
28. Rigaud M, Borkowsky W, Muresan P, et al. Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy. J Infect Dis 2008, 198:1123-1130.
29. Tangsinmankong N, Kamchaisatian W, Day NK, et al. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy. Ann Allergy Asthma Immunol 2004, 92:558-564.
30. Tarrago D, Casal J, Ruiz-Contreras J, et al. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol 2005, 12:165-170.
31. Ide C Costa, Guilardi F, Kmiliauskis MA, et al. Evaluation of humoral response to heptavalent pneumococcal conjugate vaccine in HIV-infected children. Rev Saude Publica 2008, 42:844-850.
32. Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006, 25:920-929.
33. Fernandes SJ, Slhessarenko N, Souto FJ Effects of vertical HIV infection on the persistence of anti-HBs after a schedule of three doses of recombinant hepatitis B vaccine. Vaccine 2008, 26:1032-1037.
34. Siriaksorn S, Puthanakit T, Sirisanthana T, et al. Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 2006, 24:3095-3099.
35. Lao-araya M, Puthanakit T, Aurpibul L, et al. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine 2007, 25:5324-5329.
36. Pippi F, Bracciale L, Stolzuoli L, et al. Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania. HIV Med 2008, 9:519-525.
37. Abzug MJ, Warshaw M, Rosenblatt HM, et al. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2009, 200:935-946.
38. Weinberg A, Gona P, Nachman SA, et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 2006, 193:302-311.
39. Weinberg A, Huang S, Fenton T, et al. Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatment. J Acquir Immune Defic Syndr 2009, 52:17-24.
40. Siberry GK, Coller RJ, Henkle E, et al. Antibody response to hepatitis A immunization among human immunodeficiency virus-infected children and adolescents. Pediatr Infect Dis J 2008, 27:465-468.
41. Tanzi E, Esposito S, Bojanin J, et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006, 78:440-445.
42. Montoya CJ, Toro MF, Aguirre C, et al. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 2007, 102:501-508.
43. Vigano A, Zuccotti GV, Pacei M, et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 48:289-296.
44. Aurpibul L, Puthanakit T, Siriaksorn S, et al. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy. HIV Med 2006, 7:467-470.
45. Berkelhamer S, Borock E, Elsen C, et al. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis 2001, 32:1090-1104.
46. Lima M, De Menezes Succi RC, Santos AM Nunes Dos, et al. Rubella immunization in human immunodeficiency virus type 1-infected children: cause for concern in vaccination strategies. Pediatr Infect Dis J 2004, 23:604-607.
47. Aurpibul L, Puthanakit T, Sirisanthana T, et al. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007, 45:637-642.
48. Bekker V, Scherpbier H, Pajkrt D, et al. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics 2006, 118:e315-e322.
49. Levin MJ, Gershon AA, Weinberg A, et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis 2006, 194:247-255.
50. King JC, Fast PE, Zangwill KM, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001, 20:1124-1131.
51. Zaccarelli-Filho CA, Ono E, Machado DM, et al. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression. Cytometry B Clin Cytom 2007, 72:14-21.
52. Farquhar C, Wamalwa D, Selig S, et al. Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination. Pediatr Infect Dis J 2009, 28:295-299.
53. Pensieroso S, Cagigi A, Palma P, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci USA 2009, 106:7939-7944.
54. Levin MJ, Song LY, Fenton T, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008, 26:4210-4217.
55. Melvin AJ, Mohan KM Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 2003, 111:e641-e644.
56. Moir S, Fauci AS B cells in HIV infection and disease. Nat Rev Immunol 2009, 9:235-245.
57. Vaccines 2008, Saunders, Amsterdam. 5th edn. S. Plotkin, W. Orenstein, P. Offit (Eds.).
58. Moir S, Fauci AS Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 2008, 122:12-19.
59. D'Orsogna LJ, Krueger RG, McKinnon EJ, et al. Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. AIDS 2007, 21:1747-1752.
60. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523-526.
61. Koegl C, Wolf E, Hanhoff N, et al. Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res 2009, 14:277-283.
62. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006, 194:725-733.
63. Titanji K, Chiodi F, Bellocco R, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 2005, 19:1947-1955.
64. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008, 359:2233-2244.